

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

PE anti-mouse/human CD44

RRID:AB_312958

Type: Antibody

Proper Citation

BioLegend Cat# 103007, RRID:AB_312958

Antibody Information

URL: http://antibodyregistry.org/AB_312958

Proper Citation: BioLegend Cat# 103007, RRID:AB_312958

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_312958

Vendor: BioLegend

Catalog Number: 103007

Alternative Catalog Numbers: 103023, 103024, 103008

Record Creation Time: 20250820T011411+0000

Record Last Update: 20250820T102317+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse/human CD44.

No alerts have been found for PE anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wang Y, et al. (2025) Cognate interaction-dependent pathogenicity of meningeal B cells drives neuroinflammation relapse. *Immunity*, 58(9), 2256.

Kawarizadeh K, et al. (2025) Absence of BCAP in myeloid cells abrogates M2 macrophage differentiation and promotes anti-tumor immunity. *iScience*, 28(11), 113723.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. *Cell reports. Medicine*, 102515.

Bernaleau L, et al. (2025) CCDC134 controls TLR biogenesis through the ER chaperone Gp96. *The Journal of experimental medicine*, 222(3).

Guruprasad P, et al. (2025) Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. *Nature protocols*.

Yang CL, et al. (2024) PDIA3 orchestrates effector T cell program by serving as a chaperone to facilitate the non-canonical nuclear import of STAT1 and PKM2. *Molecular therapy : the journal of the American Society of Gene Therapy*, 32(8), 2778.

Shi W, et al. (2024) Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. *Cell reports. Medicine*, 5(5), 101531.

Straub A, et al. (2023) Recruitment of epitope-specific T cell clones with a low-avidity threshold supports efficacy against mutational escape upon re-infection. *Immunity*, 56(6), 1269.

Morimoto J, et al. (2022) Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity. *Cell reports*, 38(7), 110384.

Nakahama T, et al. (2021) Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi-Goutières-syndrome-like encephalopathy. *Immunity*, 54(9), 1976.

Ringel AE, et al. (2020) Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. *Cell*, 183(7), 1848.

Du L, et al. (2019) IGF-2 Preprograms Maturing Macrophages to Acquire Oxidative Phosphorylation-Dependent Anti-inflammatory Properties. *Cell metabolism*, 29(6), 1363.

Wang D, et al. (2018) The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation. *Immunity*, 48(4), 659.